Dendritic Cell-Based Immunotherapy for Prostate Cancer
Dendritic cells (DCs) are professional antigen-presenting cells (APCs), which display an extraordinary capacity to induce, sustain, and regulate T-cell responses providing the opportunity of DC-based cancer vaccination strategies. Thus, clinical trials enrolling prostate cancer patients were conduct...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2010/517493 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850162970482442240 |
|---|---|
| author | Hanka Jähnisch Susanne Füssel Andrea Kiessling Rebekka Wehner Stefan Zastrow Michael Bachmann Ernst Peter Rieber Manfred P. Wirth Marc Schmitz |
| author_facet | Hanka Jähnisch Susanne Füssel Andrea Kiessling Rebekka Wehner Stefan Zastrow Michael Bachmann Ernst Peter Rieber Manfred P. Wirth Marc Schmitz |
| author_sort | Hanka Jähnisch |
| collection | DOAJ |
| description | Dendritic cells (DCs) are professional antigen-presenting cells (APCs), which display an extraordinary capacity to induce, sustain, and regulate T-cell responses providing the opportunity of DC-based cancer vaccination strategies. Thus, clinical trials enrolling prostate cancer patients were conducted, which were based on the administration of DCs loaded with tumor-associated antigens. These clinical trials revealed that DC-based immunotherapeutic strategies represent safe and feasible concepts for the induction of immunological and clinical responses in prostate cancer patients. In this context, the administration of the vaccine sipuleucel-T consisting of autologous peripheral blood mononuclear cells including APCs, which were pre-exposed in vitro to the fusion protein PA2024, resulted in a prolonged overall survival among patients with metastatic castration-resistent prostate cancer. In April 2010, sipuleucel-T was approved by the United States Food and Drug Administration for prostate cancer therapy. |
| format | Article |
| id | doaj-art-eecbf940fae14315b88f39dcc12e6edd |
| institution | OA Journals |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-eecbf940fae14315b88f39dcc12e6edd2025-08-20T02:22:25ZengWileyClinical and Developmental Immunology1740-25221740-25302010-01-01201010.1155/2010/517493517493Dendritic Cell-Based Immunotherapy for Prostate CancerHanka Jähnisch0Susanne Füssel1Andrea Kiessling2Rebekka Wehner3Stefan Zastrow4Michael Bachmann5Ernst Peter Rieber6Manfred P. Wirth7Marc Schmitz8Institute of Immunology, Medical Faculty, Technical University of Dresden, Fetscherstr. 74, 01307 Dresden, GermanyDepartment of Urology, Medical Faculty, Technical University of Dresden, 01307 Dresden, GermanyTranslational Sciences and Safety, Novartis Biologic, 4002 Basel, SwitzerlandInstitute of Immunology, Medical Faculty, Technical University of Dresden, Fetscherstr. 74, 01307 Dresden, GermanyDepartment of Urology, Medical Faculty, Technical University of Dresden, 01307 Dresden, GermanyInstitute of Immunology, Medical Faculty, Technical University of Dresden, Fetscherstr. 74, 01307 Dresden, GermanyInstitute of Immunology, Medical Faculty, Technical University of Dresden, Fetscherstr. 74, 01307 Dresden, GermanyDepartment of Urology, Medical Faculty, Technical University of Dresden, 01307 Dresden, GermanyInstitute of Immunology, Medical Faculty, Technical University of Dresden, Fetscherstr. 74, 01307 Dresden, GermanyDendritic cells (DCs) are professional antigen-presenting cells (APCs), which display an extraordinary capacity to induce, sustain, and regulate T-cell responses providing the opportunity of DC-based cancer vaccination strategies. Thus, clinical trials enrolling prostate cancer patients were conducted, which were based on the administration of DCs loaded with tumor-associated antigens. These clinical trials revealed that DC-based immunotherapeutic strategies represent safe and feasible concepts for the induction of immunological and clinical responses in prostate cancer patients. In this context, the administration of the vaccine sipuleucel-T consisting of autologous peripheral blood mononuclear cells including APCs, which were pre-exposed in vitro to the fusion protein PA2024, resulted in a prolonged overall survival among patients with metastatic castration-resistent prostate cancer. In April 2010, sipuleucel-T was approved by the United States Food and Drug Administration for prostate cancer therapy.http://dx.doi.org/10.1155/2010/517493 |
| spellingShingle | Hanka Jähnisch Susanne Füssel Andrea Kiessling Rebekka Wehner Stefan Zastrow Michael Bachmann Ernst Peter Rieber Manfred P. Wirth Marc Schmitz Dendritic Cell-Based Immunotherapy for Prostate Cancer Clinical and Developmental Immunology |
| title | Dendritic Cell-Based Immunotherapy for Prostate Cancer |
| title_full | Dendritic Cell-Based Immunotherapy for Prostate Cancer |
| title_fullStr | Dendritic Cell-Based Immunotherapy for Prostate Cancer |
| title_full_unstemmed | Dendritic Cell-Based Immunotherapy for Prostate Cancer |
| title_short | Dendritic Cell-Based Immunotherapy for Prostate Cancer |
| title_sort | dendritic cell based immunotherapy for prostate cancer |
| url | http://dx.doi.org/10.1155/2010/517493 |
| work_keys_str_mv | AT hankajahnisch dendriticcellbasedimmunotherapyforprostatecancer AT susannefussel dendriticcellbasedimmunotherapyforprostatecancer AT andreakiessling dendriticcellbasedimmunotherapyforprostatecancer AT rebekkawehner dendriticcellbasedimmunotherapyforprostatecancer AT stefanzastrow dendriticcellbasedimmunotherapyforprostatecancer AT michaelbachmann dendriticcellbasedimmunotherapyforprostatecancer AT ernstpeterrieber dendriticcellbasedimmunotherapyforprostatecancer AT manfredpwirth dendriticcellbasedimmunotherapyforprostatecancer AT marcschmitz dendriticcellbasedimmunotherapyforprostatecancer |